• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 25, 2025
Finance

Pair of European start-ups launch with innovative antibodies: Finance Report

Plus: Flagship unveils disease interception play Etiome; Verastem raises $75M PIPE; and more
Read More
BioCentury | Sep 19, 2024
Discovery & Translation

Science Spotlight: Cancer prognosis via deep learning, new protein degraders, and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Apr 12, 2024
Product Development

Cambrian explosion of ADCs at AACR24

Conference showcases six emerging ADC payload types, and trends in antigen pairs for bispecific ADCs
Read More
BioCentury | Feb 17, 2024
Discovery & Translation

Science spotlight: a germinal center B cell-activating adjuvant, peptide-conjugated CARs and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Nov 30, 2023
Deals

ImmunoGen’s commitment to Elahere pays off with $10.1B AbbVie takeout

Pharma sees opportunities for label expansions as it builds pipeline, gains commercial presence in solid tumors
Read More
BioCentury | Sep 5, 2023
Discovery & Translation

Epitope editing of immunotherapies; plus NovoBiotic’s antibiotic and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Apr 25, 2023
Data Byte

Aggressive cuts part of Novartis’ focus on higher-potential pipeline

The pharma’s latest quarterly update revealed a pruning of 10% of its pipeline, including several early-stage cancer programs
Read More
BioCentury | Dec 20, 2022
Product Development

Stem cell transplants aim for next level of sophistication

Gene editing stem cell transplants makes targeted myeloid, T cell cancer therapies safer: ASH 2022
Read More
BioCentury | Dec 20, 2022
Deals

Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal

Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more 
Read More
BioCentury | Aug 31, 2022
Regulation

Aug. 31 Quick Takes: FDA authorizes pair of bivalent COVID-19 vaccines

Plus Sanofi gains FDA approval of ASMD drug, a clinical miss for AnaptysBio, Ocean’s SPAC deal, IncellDx’s long COVID diagnostic and more
Read More
Items per page:
1 - 10 of 95